Clinical Trials · NCT00166725
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Novartis
- Enrollment
- 40
- Start date
- Feb 2004
- Locations
- 1 site, Italy
- Primary endpoint
- Time to 25% decrease in chromogranin A plasma level (evaluation every 4 weeks for the first 12 weeks and every 12 weeks after)